Steven Lichtman (William Blair) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Steven Lichtman's stock ratings?

About 38% of Steven's ratings were profitable over a one-year hold, with an average return of -9.5% per rating, measured by 13Foresight from historical prices.

Q: How is Steven ranked?

Steven Lichtman is ranked #2489 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Steven Lichtman

Steven Lichtman

William Blair

Wall Street Analyst

★☆☆☆☆

#2489

on 13Foresight · ranked by our own returns

38%

Success Rate

-9.6%

Average Return

11 of 29 calls profitable · -59531.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 38% of Steven Lichtman's ratings turned a profit when each position was held for 1 year — averaging -9.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

26 Buy 11 Hold 0 Sell

Steven's Stock Coverage 32 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
MMED MiniMed Group, Inc.	Jun 17, 2026	BUY	Strong Buy +47.2% avg upside 13 analysts	—	·
COO Cooper Co	Jun 05, 2026	BUY	Buy +102.3% avg upside 21 analysts	—	+0.0%
PODD Insulet	Jun 04, 2026	BUY	Strong Buy +79.0% avg upside 32 analysts	—	+2.2%
GKOS Glaukos	Jun 03, 2026	BUY	Strong Buy +5.5% avg upside 20 analysts	—	·
DXCM Dexcom	May 15, 2026	BUY	Strong Buy +38.6% avg upside 32 analysts	—	+18.7%
ENOV Enovis	May 08, 2026	BUY	Strong Buy +216.5% avg upside 37 analysts	—	-6.2%
RXST RxSight	May 08, 2026	HOLD	Hold +132.6% avg upside 13 analysts	—	+2.6%
SGHT Sight Sciences	May 07, 2026	BUY	Buy +52.9% avg upside 13 analysts	—	-7.2%
CH:ALC Alcon	May 06, 2026	HOLD	Buy +33.9% avg upside 35 analysts	—	·
SYK Stryker	May 01, 2026	BUY	Strong Buy +24.0% avg upside 36 analysts	—	+2.2%
ZBH Zimmer Biomet Holdings	Apr 29, 2026	HOLD	Buy +27.6% avg upside 37 analysts	—	+10.8%
MNKD MannKind	Sep 05, 2025	BUY	Buy +78.6% avg upside 22 analysts	$15.00 280.65% Upside	-40.2%
BSX Boston Scientific	Aug 03, 2025	HOLD	Strong Buy +72.9% avg upside 38 analysts	$118.00 160.53% Upside	-57.6%
BWAY Brainsway	May 14, 2025	BUY	Strong Buy -11.7% avg upside 9 analysts	$7.50 49.60% Downside	+217.8%
GMED Globus Medical	May 09, 2025	HOLD	Strong Buy +21.0% avg upside 24 analysts	$78.00 1.55% Downside	+39.6%
MMSI Merit Medical Systems	Feb 26, 2025	BUY	Strong Buy +35.1% avg upside 15 analysts	$116.00 72.61% Upside	-22.3%
ANGO AngioDynamics	Jan 10, 2025	BUY	Strong Buy +39.9% avg upside 9 analysts	$16.00 31.59% Upside	-19.8%
PEN Penumbra	Dec 16, 2024	BUY	Buy +4.4% avg upside 23 analysts	$275.00 13.33% Downside	+24.6%
STAA Staar Surgical	Nov 01, 2024	HOLD	Hold +14.2% avg upside 16 analysts	—	-9.4%
MDT Medtronic	Aug 21, 2024	HOLD	Buy +23.5% avg upside 38 analysts	$94.00 18.51% Upside	+7.5%
TNDM Tandem Diabetes Care	Aug 02, 2024	BUY	Buy +116.0% avg upside 29 analysts	$58.00 279.13% Upside	-63.0%
IART Integra Lifesciences	May 07, 2024	HOLD	Buy +136.2% avg upside 21 analysts	—	-49.2%
MODD Modular Medical	Sep 19, 2023	BUY	Strong Buy +45.6% avg upside 3 analysts	$3.50 32.11% Downside	+94.8%
MOTS Motus Gi Holdings	Feb 06, 2023	HOLD	Buy +49433233.3% avg upside 6 analysts	—	·
ORGO Organogenesis Holdings	Aug 10, 2022	HOLD	Strong Buy +375.4% avg upside 8 analysts	—	-42.8%
HSDT Solana Company	Dec 31, 2020	HOLD	Strong Buy +1277.5% avg upside 8 analysts	—	-60.7%
LFWD Lifeward	Dec 18, 2018	HOLD	Strong Buy +5.4% avg upside 8 analysts	—	-52.4%
CI Cigna	Feb 08, 2018	BUY	Strong Buy +24.2% avg upside 29 analysts	$237.00 15.15% Downside	-4.2%
CYPH Cypherpunk Technologies	May 27, 2016	HOLD	Buy +1087.0% avg upside 9 analysts	—	·
NUWE Nuwellis	Mar 04, 2016	HOLD	Strong Buy +16978.6% avg upside 7 analysts	—	-80.2%
NSPR InspireMD	Mar 13, 2015	HOLD	Strong Buy +447.3% avg upside 8 analysts	—	-75.7%
STXS Stereotaxis	Oct 07, 2011	HOLD	Strong Buy +126.1% avg upside 7 analysts	—	-88.8%

🔒 27 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Steven Lichtman — Frequently Asked Questions

How accurate are Steven Lichtman's stock ratings?

Based on the calls 13Foresight could measure, about 38% of Steven's ratings were profitable over a one-year hold, with an average return of -9.5% per rating, or -23.1% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Steven ranked on 13Foresight?

Steven Lichtman is currently ranked #2489 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Steven cover?

Steven most recently has ratings on MMED, COO, PODD, GKOS, DXCM, ENOV, RXST, SGHT, CH:ALC, SYK, ZBH, MNKD and 20 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!